This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
GIA initiates research coverage on the global Cell-Based Assays market, as part of its ongoing multiple research projects on diverse industries and markets. The soon to be released report identifies strong investments in new drug development, technological innovations and availability of high throughput screening (HTS) systems, as primary growth drivers in the market.
San Jose, California (PRWEB) July 17, 2014
Follow us on LinkedIn GIA is pleased to announce the launch of a major research program analysing the trends impacting the market for Cell-Based Assays. Invited to participate in this comprehensive grassroots level global research initiative are senior industry executives, domain experts, technologists and market strategists. The new report to be issued shortly will offer accurate assessment of global market developments including major technologies, trends and challenges, together with descriptive, exploratory, and quantitative analysis of major product and geographic market segments. For details about how you can participate in this primary research program to include your inputs prior to the publication, please click here.
The drug discovery sector is the major end-user of cell-based assays. Characterized by versatility, cell-based assays represent a powerful research tool that provides valuable information for successful R&D. Cell-based assays also facilitate in studying biological characteristics of target drug compounds and their impact on cells/cellular systems in terms of activation of cell receptors, alteration in gene activity and expression of proteins. These assays are therefore emerging as a preferred tool for screening potential drug molecules. Cell-based assays also play an important role in toxicology testing in early stages of drug discovery, thereby reducing overall costs and the risk of clinical trial failures. Additionally, the market is being driven by the availability of high throughput screening (HTS) systems and advanced technological innovations such as development of label-free cell-based assays. Growing focus on expansion of drug portfolios and the ensuing increased investments in new drug development by pharma majors will generate lucrative opportunities for growth in the coming years.
The upcoming report will offer coverage on major companies including BD Biosciences, Beckman Coulter Inc., EMD Millipore, GE Healthcare Life Sciences, Life Technologies Corp, and Qiagen NV, among others.
In addition, the study will also provide:
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
For the original version on PRWeb visit: http://www.prweb.com/releases/cell_based_assays_market/healthcare_industry/prweb12026138.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.